FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

APOLLOHOSP

2,430.65
+40.75 (1.71%)
Updated 03:29 04/12 IST

APOLLOHOSP Buy or Sell - FrontPage Forums

1 Users have submitted 1 trade ideas of Rs. 12,545 for APOLLOHOSP
Disclaimer
100% Bullish
0% Bearish

APOLLOHOSP Buy or Sell - Brokerage Reports

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
1800
Consensus Potential
-32.77%
See APOLLOHOSP Share Price Targets >>

APOLLOHOSP Ratings

Long term APOLLOHOSP rating by FrontPage users
5/5 (3 Ratings)
Find answers to all your questions on live APOLLOHOSP message board: Is APOLLOHOSP buy or sell? Should I buy APOLLOHOSP shares? Why are APOLLOHOSP shares falling? Should I invest in APOLLOHOSP stock?

  1. Home
  2. APOLLOHOSP Forum

APOLLOHOSP Share Price Discussion


Type
Buy
Instrument
APOLLOHOSP
Entry Price
₹2,422
Price@Trade
₹2,424.95
Target Price
₹2,450
Stop Price
₹2,410
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹242,200 approx for 100 Qty
Status
Waiting for entry
Like
Reply
K
Reputation: 7,130 • Today 5:48 AM

Type
Sell
Instrument
HDFCBANK DEC20 FUT
Entry Price
₹1,391.35
Price@Trade
₹1,391.65
Target Price
₹1,381.75
Stop Price
₹1,396
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹164,053.26 approx for 550 Qty
Status
Waiting for entry
Like
Reply
S
Reputation: -32,461 • Today 5:48 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29000 PE
Entry Price
₹380
Price@Trade
₹149.65
Target Price
₹760
Stop Price
₹250
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹342,000 approx for 900 Qty
Status
Waiting for entry
Like
Reply
J
Reputation: 26,211 • Today 5:48 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29000 PE
Entry Price
₹140
Price@Trade
₹150.35
Target Price
₹180
Stop Price
₹120
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹350,000 approx for 2500 Qty
Status
Waiting for entry
Like
Reply
S
Reputation: 15,121 • Today 5:48 AM

Type
Buy
Instrument
NIFTY 10DEC20 13350 CE
Entry Price
₹52
Price@Trade
₹53.65
Target Price
₹68
Stop Price
₹45
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹7,800 approx for 150 Qty
Status
Waiting for entry
Like
Reply
N
Reputation: 8,341 • Today 5:48 AM
RBI maintains status quo, here are top 11 rate-sensitive stocks that are attractive buys
Interest rates are likely to remain low for some more time and hence rate-sensitive sectors such as banks, real estate, NBFCs and automobiles will remain in focus.
Moneycontrol
Like
Reply
A
Reputation: -35,121 • Today 5:47 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29700 PE
Entry Price
₹380
Price@Trade
₹381.75
Target Price
₹760
Stop Price
₹250
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹285,000 approx for 750 Qty
Status
Waiting for entry
Like
Reply
R
Reputation: -44,874 • Today 5:47 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29700 PE
Entry Price
₹380
Price@Trade
₹380
Target Price
₹760
Stop Price
₹250
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹76,000 approx for 200 Qty
Status
Active
Like
Reply
S
Reputation: -47,349 • Today 5:47 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29700 PE
Entry Price
₹380
Price@Trade
₹379.5
Target Price
₹760
Stop Price
₹250
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹38,000 approx for 100 Qty
Status
Waiting for entry
Like
Reply
R
Reputation: 1,263 • Today 5:47 AM

Type
Sell
Instrument
COPPER 31DEC20 FUT
Entry Price
₹595.95
Price@Trade
₹595.7
Target Price
₹590
Stop Price
₹600
Valid Till
Dec 31, 2020 11:20 AM
Margin
₹136,115.63 approx for 2500 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
BANKNIFTY 10DEC20 29700 PE
Entry Price
₹378
Price@Trade
₹379.6
Target Price
₹550
Stop Price
₹325
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹9,450 approx for 25 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 5:47 AM

Update
Trade Entered
Entry Price
₹378
G
Reputation: -73 • Today 5:46 AM

Type
Sell
Instrument
NIFTY 10DEC20 13300 CE
Entry Price
₹74
Price@Trade
₹73.8
Target Price
₹50
Stop Price
₹95
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹141,977.83 approx for 75 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 5:47 AM

Update
Trade Entered
Entry Price
₹74
P
Reputation: -48,727 • Today 5:46 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29700 PE
Entry Price
₹380
Price@Trade
₹382.1
Target Price
₹760
Stop Price
₹250
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹19,000 approx for 50 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 5:47 AM

Update
Trade Entered
Entry Price
₹380
G
Reputation: 4,650 • Today 5:46 AM

Type
Buy
Instrument
BANKNIFTY 31DEC20 FUT
Entry Price
₹29,848.7
Price@Trade
₹29,848.7
Target Price
₹29,960
Stop Price
₹29,780
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹159,114.02 approx for 25 Qty
Status
Active
Like
Reply
A
Reputation: -35,121 • Today 5:45 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 29700 PE
Entry Price
₹380
Price@Trade
₹377.5
Target Price
₹760
Stop Price
₹250
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹9,500 approx for 25 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Ashwini Patra @ashwinibabu
Today 5:46 AM

Update
Exited before entry
Price @ Update
₹379.85
G
Reputation: -73 • Today 5:45 AM

Type
Buy
Instrument
NIFTY 10DEC20 13250 CE
Entry Price
₹95  ₹96.65
Price@Trade
₹96.05
Target Price
₹130
Stop Price
₹60
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹7,248.75 approx for 75 Qty
Status
Active
Like
Reply (2)
See all replies
Gauravliya @gauravliya
Today 5:47 AM

Update
Entry Price Modified
Price @ Update
₹96.65
Original Entry Price
₹95
New Entry Price
₹96.65
TrackerBot @trackerbot
Today 5:47 AM

Update
Trade Entered
Entry Price
₹96.65

Type
Buy
Instrument
NIFTY 10DEC20 13200 CE
Entry Price
₹122.4
Price@Trade
₹122.4
Target Price
₹140
Stop Price
₹114
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹9,180 approx for 75 Qty
Status
Active
Like
Reply
D
Reputation: -357 • Today 5:45 AM

Type
Buy
Instrument
INDIGO DEC20 FUT
Entry Price
₹1,744
Price@Trade
₹1,744
Target Price
₹1,758
Stop Price
₹1,735
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹243,550 approx for 500 Qty
Status
Active
Like
Reply

Type
Sell
Instrument
NIFTY 25FEB21 FUT
Entry Price
₹13,292.15
Price@Trade
₹13,292.15
Target Price
₹5,000
Stop Price
₹17,000
Valid Till
Feb 25, 2021 3:20 AM
Margin
₹154,723.23 approx for 75 Qty
Status
Active
Like
Reply
J
Reputation: 26,211 • Today 5:45 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 30700 CE
Entry Price
₹100
Price@Trade
₹108.1
Target Price
₹180
Stop Price
₹50
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹100,000 approx for 1000 Qty
Status
Waiting for entry
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • APOLLOHOSP - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization16,985.86
    Enterprise Value19,761.2
    Price to Earnings63.45
    Price to Book Value4.37
    Return on Capital Employed0.09
    Return on Equity0.06
    Face Value5
    Dividend YieldNA
  • APOLLOHOSP - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    10-Dec-19ICICIdirect.comBuy1,800
    26-Jun-19Indiabulls VenturesBuy1,580
    31-May-19ICICIdirect.comBuy1,450
    12-Feb-19EdelweissBuy1,700
    11-Feb-19ICICIdirect.comBuy1,400
    APOLLOHOSP Brokerage Price Target
  • APOLLOHOSP Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 42400244524002434.65
    Dec 325012501.052371.92389.9
    Dec 22474.72485.052375.452411.55
    Dec 123842508.852349.052463
    Nov 272314.95237522982347.9
  • APOLLOHOSP Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹2,271.21
    30 Day Moving Average₹2,212.36
    50 Day Moving Average₹2,178.06
    100 Day Moving Average₹1,903.96
    200 Day Moving Average₹1,659.42
  • APOLLOHOSP - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue7,1836,441.770.12
    Operating Profit830774.010.07
    Profit Before Tax330358.92-0.08
    Net Income233285.15-0.18
  • APOLLOHOSP - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds3,8843,6940.05
    Total Liabilities4,5454,688-0.03
    Total Assets8,4288,3820.01
  • APOLLOHOSP - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity539623.51-0.14
    Cash from Investing Activity-378-817.62-0.54
    Cash from Financing Activity-106211.16-1.5
    Net Cash Flow5417.052.17
  • APOLLOHOSP - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.04
    Return on Equity0.060.08
    Return on Capital Employed0.090.09
  • APOLLOHOSP - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.56
    3 Year CAGR Growth in Operating Profit0.25
    3 Year CAGR Growth in EBIDTA0.19
    3 Year CAGR Growth in Net Income-0.33
    3 Yr CAGR Growth - Diluted EPS-0.33
  • APOLLOHOSP - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.16
    5 Year CAGR Growth in Operating Profit0.5
    5 Year CAGR Growth in EBIDTA0.43
    5 Year CAGR Growth in Net Income-0.25
    3 Yr CAGR Growth - Diluted EPS-0.25
  • APOLLOHOSP - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 5:48 AM
    Apollo Hospitals shares gain after board approves raising up to Rs 1,500 crore
    Moneycontrol
    NewsBot
    Nov 21 10:43 AM
    ZS PRIZE: Healthcare innovation challenge seeks ideas for Rs 1 crore prize money
    Moneycontrol
    NewsBot
    Nov 20 5:01 AM
    Apollo Hospitals rises 4% on Covid test collaboration with Tata Medical and Diagnostics
    The Economic Times
    NewsBot
    Nov 20 4:18 AM
    How India’s ecosystem is gearing up for the smooth rollout of Covid-19 vaccines
    Moneycontrol
    NewsBot
    Nov 19 10:51 AM
    Apollo Hospitals, TataMD collaborate to launch 'TataMD CHECK' test for COVID-19
    The Economic Times
    NewsBot
    Nov 17 6:28 AM
    Hold Apollo Hospitals; target of Rs 2310: ICICI Direct
    Moneycontrol
    NewsBot
    Nov 12 7:41 AM
    World Pneumonia Day: Weak lungs, poor immune system can increase Covid severity in adults
    The Economic Times
    NewsBot
    Nov 11 4:03 AM
    Apollo Hospitals Q2 net drops 30% to Rs 60 crore; board approves raising Rs 1,500 crore
    Moneycontrol
    NewsBot
    Oct 31 10:41 AM
    A lot of unreliable rapid antigen tests masking real extent of COVID-19 in capital: Experts
    The Economic Times
    NewsBot
    Oct 27 5:31 AM
    Morgan Stanley sees $2.5 billion inflows in these stocks after MSCI index revision
    The Economic Times
  • APOLLOHOSP - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • APOLLOHOSP - More Information

    keyboard_arrow_down

    Apollo Hospitals Enterprises Ltd:
    Along with its subsidiaries, Apollo Hospitals Enterprise Limited has been providing healthcare services in India with an international venture. Primary, Secondary, and Tertiary care facilities are comprised of the company. Including cardiac sciences, oncology, critical care, neurosciences, orthopaedics, gastroenterology, and transplants tertiary care hospitals provide care in around 55 specialities. Along with this, the firm is providing different services, including project consultancy, health insurance, education and training program, and research services. Besides that pharmacies, primary care clinics, birthing centres, single-speciality clinics, primary health centres and diagnostic chains, dental clinics, and day-care and home healthcare centres operated by the firm. As of January 2019, the company started running 71 hospitals possessing 10,000 beds; 3,000 pharmacies. The company has 90 primary care and diagnostic clinics and approximately 110 telemedicine centres. Apollo Hospitals Enterprise Limited incepted in 1979 and has it headquarter in Chennai, India.
    Company Information:
    The company, seven years after its inception, added 46 beds in 1985. This group introduced the idea of developing corporate healthcare in India for the first time. Apollo introduced such hospitals which were providing the facility of Magnetic Resonance Imaging (MRI) even in the year of 1989, along with SOMATOMCR which is a Computed Tomography scanner for the entire body; Breast-scanning equipment such as Dideoendoscopy and Mammography were introduced too.
    In August 1991 The Apollo School of Nursing was founded, offering a 3-year diploma programme with an internship in the hospital. The hospital added 16 intensive care beds in 1992, along with developing its equipment in different departments. In 1993, Apollo Cancer Hospital, a premium cancer treatment and research centre, was established with 150-beds in Chennai. Along with that, it introduced the bone marrow transplant facility, developing its cancer project.
    Apollo Hospital Enterprise Limited (AHEL), developed a cancer hospital again in Hyderabad in 1995. In the same year, it was joined in the mission of eradicating Tuberculosis in India under WHO.
    Signing an MOU with Jardine of UK, AHEL adopted the health maintenance organisations (HMO) in 1997, a concept the nation witnessed for the first time. In the next year 1998, an MOU was signed between AHEL and Sri Lankan Government for building a super-speciality hospital in Colombo, which opened the door of AHEL’s international intervention.
    In 2002, the hospital captured the 50.26 % of in the Duncan Gleneagles Hospital against a minimal amount of Rs.3 crore. A tie-up with ICICI Lombard took place in 2003, introducing an accident insurance product. Developing a technology partnership with the Defence Research & Development Organisation (DRDO), AHEL enhanced its strength in 2004.
    Apollo Hospital Delhi was awarded a JCI certificate in 2005 for providing care in a safe environment. In June 2007, AHEL introduced Health City, for the first time in Asia, at Hyderabad with a holistic healthcare delivery facility, with an area of 33 acres mot only for treatment and research but also for hospitality management. In January 2008, an agreement took place between the hospital and the real estate firm Hindustan Construction Co (HCC), for launching a top-class medi-city inside the hill station Lavasa in Maharashtra.
    In June 2012, AHEL declared that International Finance Corporation (IFC) had requested the company for the transformation of the balance loan amount of US$ 7.50 million of Foreign Currency Convertible Bonds (FCCBs) into equity shares. Through making a primary equity infusion of Rs.450 crore, World Bank affiliated International Finance Corporation acquired a 29.03% stake in Apollo Health and Lifestyle Limited (AHLL), a subsidiary of the company, in the year of December 2016.
    Net profit of the company enhanced 28.57% to Rs.76.68 crore in the first quarter of 2019, ending in March against that of the previous quarter ended on March 2018 with Rs.59.64 crore. Similarly, the sales are enhanced by 16.30% to Rs.2167.11 crore in the first quarter of 2019 compared to the sales amount of Rs.1863.42 crore, that the company acquired in the first quarter of 2018.
    How Apollo Hospitals Enterprises Ltd, is categorised as Healthcare Sector, and Hospitals and Medical services Industry :
    Hospital and Medical Services Industry includes companies that are engaged in offering healthcare medical services and also operating standalone pharmacies. They offer services like hospitals, hospital-based pharmacies, consultancy services and projects. Some companies also provide health insurance services, research services and education and training programs.
    Apollo Hospitals Enterprises Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Apollo Hospitals Enterprises Ltd, Competitors and Sector Peers:
    ADS Diagnostic Ltd. ADSDIA
    ANG Lifesciences India Ltd. ANGLIF
    Artemis Global Life Sciences Ltd. ARTGLO
    Aspira Pathlab & Diagnostics Ltd. ASPPAT
    Aster DM Healthcare Ltd. ASTDMH
    Birla Pacific Medspa Ltd. BIRPAC
    CDR Health Care Ltd. CDRHEA
    Chennai Meenakshi Multispeciality Hospital Ltd. DEVHOS
    Deccan Health Care Ltd. DECHEA
    Dhanvantri Jeevan Rekha Ltd. DHAJEE
    Dolphin Medical Services Ltd. DOLMED
    Dr. Agarwal's Eye Hospital Ltd. DRAGA
    Dr. Lal Pathlabs Ltd. DRLAL
    Dr. Lalchandani Labs Ltd. DRLALL
    Fortis Healthcare Ltd. FORHEA
    Fortis Malar Hospitals Ltd. MALHOS
    Healthcare Global Enterprises Ltd. HEAGLO
    Indo-Global Enterprises Ltd. INDOE
    Indraprastha Medical Corporation Ltd. INDRME
    Kids Medical Systems Ltd. KIDMED
    KMC Speciality Hospitals (India) Ltd. SEAHOS
    Kovai Medical Center and Hospital Ltd. KOVMED
    Looks Health Services Ltd. MONHEA
    Lotus Eye Hospital and Institute Ltd. LOTEYE
    Medinova Diagnostic Services Ltd. MEDDIA
    Metropolis Healthcare Ltd. METHEA
    N G Industries Ltd. NGINDL
    Narayana Hrudayalaya Ltd. NARHRU
    Noida Medicare Centre Ltd. NOIMED
    Regency Hospitals Ltd. REGHOS
    Sakar Healthcare Ltd. SAKHEA
    Scandent Imaging Ltd. PHACOM
    Secunderabad Healthcare Ltd. SECHEA
    Shalby Ltd. SHALLT
    Soni Medicare Ltd. SONMED
    STG Lifecare Ltd. STGTEC
    Tejnaksh Healthcare Ltd. TEJHEA
    Thyrocare Technologies Ltd. THYTEC
    Vimta Labs Ltd. VIMLAB
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020